

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

VOLUNTARY ANNOUNCEMENT

REGISTRATION IN COLOMBIA FOR ALWIDE® PLUS BALLOON CATHETER

This announcement is made by MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement and product registration progress of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that Alwide® Plus balloon catheter (“**Alwide® Plus**”) independently developed by the Company was successfully registered in Colombia.

Alwide® Plus is the second-generation product of the Company’s Alwide® balloon catheter, which received its registration approval from the National Medical Products Administration of the People’s Republic of China on July 29, 2021 and successfully registered in Argentina in March 2022. Its key features include (i) low compliance ability enables accurate sizing; (ii) high burst pressure suits for severe calcification; and (iii) fast inflation/deflation minimizes pacing time. Compared to the first-generation product, Alwide® Plus is designed to improve burst pressure. The Company believes Alwide® Plus can reduce the challenges in valve pre- and post-dilation during TAVI (transcatheter aortic heart valve implantation) procedures.

Alwide® Plus is the third product that the Company successfully registered in Colombia after the VitaFlow Liberty™ transcatheter aortic valve implantation system (“**VitaFlow Liberty™**”), and the tip-preshaped super stiff guidewire Angelguide®, marking another solid step forward on the Company’s international roadmap, and will boost the promotion and application of VitaFlow Liberty™ in Colombia.

By order of the Board
MicroPort CardioFlow Medtech Corporation
Luo Qiyi
Chairman

Shanghai, PRC, September 27, 2022

As of the date of this announcement, the executive Directors are Mr. Chen Guoming, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Dr. Luo Qiyi, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.